Eurizon Capital SGR S.p.A. Purchases Shares of 172,472 Becton, Dickinson and Company $BDX

Eurizon Capital SGR S.p.A. purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 172,472 shares of the medical instruments supplier’s stock, valued at approximately $33,475,000.

Other large investors have also recently bought and sold shares of the company. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth about $25,000. Steph & Co. grew its holdings in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the period. Cornerstone Planning Group LLC grew its holdings in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 139 shares during the period. Accredited Wealth Management LLC grew its holdings in Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 70 shares during the period. Finally, WPG Advisers LLC grew its holdings in Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 61 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on BDX. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. TD Cowen decreased their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Evercore raised their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $183.64.

Becton, Dickinson and Company Trading Down 0.9%

NYSE:BDX opened at $147.13 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $40.54 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 10.42 and a beta of 0.22. The firm has a fifty day simple moving average of $151.63 and a two-hundred day simple moving average of $177.02. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.